<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05122806</url>
  </required_header>
  <id_info>
    <org_study_id>GroupeFDPC</org_study_id>
    <secondary_id>GFPC 08-2020</secondary_id>
    <nct_id>NCT05122806</nct_id>
  </id_info>
  <brief_title>Analysis of Biological Characteristics of Advanced ALK-rearranged NSCLC</brief_title>
  <acronym>BIOEXALK</acronym>
  <official_title>Biological Characterization of Advanced ALK-rearranged Non-small Cell Lung (NSCLC) Cancer Included in EXPLOREALK Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Groupe Francais De Pneumo-Cancerologie</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Takeda</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Groupe Francais De Pneumo-Cancerologie</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BioEXALK is a prospective study evaluating the biological characteristics of advanced&#xD;
      ALK-rearranged NSCLC treated with next generation TKIs in first line, included in the&#xD;
      national EXPLORE ALK cohort (GFPC 03-2019), a non-interventional, national, multi-center&#xD;
      cohort of ALK-rearranged NSCLC patients.&#xD;
&#xD;
      BioExALK study will be proposed to every patient included in the Explore ALK GFPC 03-2019&#xD;
      study.&#xD;
&#xD;
      Biological analysis will be performed on tumor tissue at diagnosis and at the time of disease&#xD;
      progression when available and on circulating tumor DNA (ctDNA).&#xD;
&#xD;
      For plasma testing, after obtained patient consent, blood samples will be taken and analyzed&#xD;
      at the Léon Bérard Center (Lyon).&#xD;
&#xD;
      Biological analysis on tissue obtained at diagnosis and at disease progression will be&#xD;
      collected and be sent for centralized analysis to the Rouen University Hospital.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      BioEXALK is a prospective study evaluating the biological characteristics of advanced&#xD;
      ALK-rearranged NSCLC treated with new generation TKIs in first line, included in the national&#xD;
      EXPLORE ALK cohort (GFPC 03-2019).&#xD;
&#xD;
      Explore ALK GFPC 03-2019 is a non-interventional, national, multi-center cohort of&#xD;
      ALK-rearranged NSCLC patients, whose RCB reference is 2020-A00771-38 and which obtained an&#xD;
      approval from the IDF II Ethic Committee on 25/05/2020. Biological analysis will be performed&#xD;
      on tissue at diagnosis and at the time of disease progression when available and on&#xD;
      circulating tumor DNA (ctDNA) on three timepoints (diagnosis, at first tumor evaluation and&#xD;
      at the time of disease progression).&#xD;
&#xD;
        -  Tissue : RNAseq will be performed on tumor biopsy (10 slides of 5 microns) to identify&#xD;
           the ALK fusion partner and its variant and associated co-mutations..&#xD;
&#xD;
        -  ctDNA : NGS panel on DNA including a large panel of fusions and mutations will be&#xD;
           performed on blood samples (30mL on EDTA or STRECKs tubes) at diagnosis, at the time of&#xD;
           the first evaluation and at the time of progression).&#xD;
&#xD;
      For plasma testing, after obtained patient consent, blood samples (35mL on EDTA or STRECKs&#xD;
      tubes) at diagnosis, at the first evaluation and at disease progression will be taken.&#xD;
&#xD;
      The ALKis include alectinib and brigatinib as first-line therapy or other drugs with&#xD;
      marketing authorizations (lorlatinib, entrectinib) or in early access programs (EAPs).&#xD;
&#xD;
      Liquid biopsies will be analyzed with a NGS panel allowing the identification of ALK fusion&#xD;
      partners and resistance mechanisms (mutations, fusions, copy number variations). Samples will&#xD;
      be sent for centralized analysis to the Léon Bérard Center (Lyon).&#xD;
&#xD;
      For biological analysis on tissue obtained at diagnosis, the ALK fusion partner and its&#xD;
      variant will be identified by RNAseq. Whenever a tissue re-biopsy is performed at the time of&#xD;
      disease progression as part of the standard of care management of the patient, the remaining&#xD;
      tissue sample will be collected as part of the BioExALK study, so that RNAseq analysis will&#xD;
      be performed to look for resistance mechanisms. Tissue samples (10 slides of 5 microns) will&#xD;
      be sent for centralized analysis to the Rouen University Hospital.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 22, 2021</start_date>
  <completion_date type="Anticipated">June 30, 2027</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2027</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>From date of treatment initiation up to 72 months</time_frame>
    <description>PFS assessed by local review using RECIST v1.1, defined as time from treatment initiation to the first clinical or radiological progression or death from any cause</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>From date of treatment initiation up to 72 months</time_frame>
    <description>OS defined as time from treatment initiation to death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DoR)</measure>
    <time_frame>From date of treatment initiation up to 72 months</time_frame>
    <description>DoR assessed by local review using RECIST v1.1, defined as time from treatment initiation to the first clinical or radiological progression, death, consent withdrawn, adverse event, protocol deviations, lost to follow-up, or initiation of a new line of anticancer therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Response Rate (ORR)</measure>
    <time_frame>From date of treatment initiation up to 72 months</time_frame>
    <description>ORR defined as objective response rate of complete response or partial response measured by local review RECIST v1.1.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating tumoral DNA (ctDNA) clearance on Progression Free Survival (PFS) of stage IV ALK-rearranged NSCLC patients</measure>
    <time_frame>From date of treatment initiation up to 72 months</time_frame>
    <description>ctDNA clearance will be determine as clearance of the fusion when detectable and/or clearance of relevant mutations when fusion not detected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating tumoral DNA (ctDNA) clearance on Overall Survival (OS) of stage IV ALK-rearranged NSCLC patients</measure>
    <time_frame>From date of treatment initiation up to 72 months</time_frame>
    <description>ctDNA clearance will be determine as clearance of the fusion when detectable and/or clearance of relevant mutations when fusion not detected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating tumoral DNA (ctDNA) clearance on Duration of Response (DoR) of stage IV ALK-rearranged NSCLC patients</measure>
    <time_frame>From date of treatment initiation up to 72 months</time_frame>
    <description>ctDNA clearance will be determine as clearance of the fusion when detectable and/or clearance of relevant mutations when fusion not detected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Circulating tumoral DNA (ctDNA) clearance on Overall Response Rate (ORR) of stage IV ALK-rearranged NSCLC patients</measure>
    <time_frame>From date of treatment initiation up to 72 months</time_frame>
    <description>ctDNA clearance will be determine as clearance of the fusion when detectable and/or clearance of relevant mutations when fusion not detected</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of mechanisms of resistance associated with first-line tyrosine kinase inhibitors</measure>
    <time_frame>From date of treatment initiation up to 72 months</time_frame>
    <description>The following mechanisms of resistance will be assessed: secondary mutations on ALK, mutations or translocations on other genes of interest, histological transformations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Description of mechanism of resistance associated with each ALK-fusion partner</measure>
    <time_frame>From date of treatment initiation up to 72 months</time_frame>
    <description>The following mechanisms of resistance will be assessed: secondary mutations on ALK, mutations or translocations on other genes of interest, histological transformations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Concordance between ALK fusion partner and co-mutations</measure>
    <time_frame>From date of treatment initiation up to 72 months</time_frame>
    <description>ALK fusion partner and co-mutation identifications based on liquid and tissue biopsies at Baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of presence or absence of serum Anti-ALK antibodies at diagnosis on OS</measure>
    <time_frame>From date of treatment initiation up to 72 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <condition>ALK Gene Rearrangement Positive</condition>
  <arm_group>
    <arm_group_label>Bioexalk cohort</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>All patients included in Explore ALK GFPC 03-2019 study who agree to participate in Bioexalk.</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>RNAseq</intervention_name>
    <description>Tissue : RNAseq will be performed on tumor biopsy (10 slides of 5 microns) to identify the ALK fusion partner and its variant and associated co-mutations.&#xD;
ctDNA : NGS panel on DNA including a large panel of fusions and mutations will be performed on blood samples</description>
    <arm_group_label>Bioexalk cohort</arm_group_label>
    <other_name>DNA NGS</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Stage IIIB/IV NSCLC non eligible to locoregional treatment with curative intent&#xD;
&#xD;
          -  ALK rearrangement confirmed by IHC and/or FISH or NGS according to local methods&#xD;
&#xD;
          -  Patient included in the EXPLORE ALK study&#xD;
&#xD;
          -  Age &gt; or = 18 years&#xD;
&#xD;
          -  Patient treated with first-line new generation ALKi&#xD;
&#xD;
          -  Patient agrees to sign an informed consent form and to collect blood samples at&#xD;
             inclusion, first tumor evaluation and progression and for whom tumor biopsy at&#xD;
             diagnosis is available&#xD;
&#xD;
          -  Patient enrolled in the french National Health Insurance program or with a third-&#xD;
             party payer&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who do not wish to participate in Bioexalk&#xD;
&#xD;
          -  Patients under guardianship&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Christos CHOUAID</last_name>
    <role>Study Director</role>
    <affiliation>Groupe Francais De Pneumo-Cancerologie</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Florian GUISIER</last_name>
    <phone>+33 2 32888079</phone>
    <email>florian.guisier@chu-rouen.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Aurélie SWALDUZ</last_name>
    <phone>+33 469756217</phone>
    <email>aurelie.swalduz@lyon.unicancer.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Pneumologie CHU Félix Guyon</name>
      <address>
        <city>Saint-Denis</city>
        <state>La Réunion</state>
        <zip>97400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Diane MOREAU</last_name>
      <email>diane.moreau@chu-reunion.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Aix en Provence</name>
      <address>
        <city>Aix En Provence</city>
        <zip>13616</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pneumologie CHU</name>
      <address>
        <city>Amiens</city>
        <zip>80054</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Géraldine FRANCOIS</last_name>
      <email>francois.geraldine@chu-amiens.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire</name>
      <address>
        <city>Angers</city>
        <zip>49033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier d'Annecy</name>
      <address>
        <city>Annecy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier du Morvan</name>
      <address>
        <city>Brest</city>
        <zip>29200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre François Baclesse</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pneumologie CH Métropole Savoie</name>
      <address>
        <city>Chambéry</city>
        <zip>73000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julian PINSOLLE</last_name>
      <email>julian.pinsolle@ch-metropole-savoie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologie CLCC Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lise THIBONNIER</last_name>
      <email>lise.thibonnier@clermont.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Intercommunal de Créteil</name>
      <address>
        <city>Creteil</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pneumologie CHD Vendée</name>
      <address>
        <city>La Roche-sur-Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie MARCQ</last_name>
      <email>marie-marcq@chd-vendee.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumologie Hôpital Mignot</name>
      <address>
        <city>Le Chesnay</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile DUJON</last_name>
      <email>cdujon@ch-versailles.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumologie CH</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Olivier MOLINIER</last_name>
      <email>omolinier@ch-lemans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologie Centre Oscar Lombret</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric DANSIN</last_name>
      <email>e-dansin@o-lambret.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumologie Hôpital Calmette</name>
      <address>
        <city>Lille</city>
        <zip>59000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexis CORTOT</last_name>
      <email>elexis.cortot@chru-lille.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumologie CHU Limoges</name>
      <address>
        <city>Limoges</city>
        <zip>87042</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital du Scorff</name>
      <address>
        <city>Lorient</city>
        <zip>56100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pneumologie Hôpital privé Jean Mermoz</name>
      <address>
        <city>Lyon</city>
        <zip>69085</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre BOMBARON</last_name>
      <email>p.bombaron@orange.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Léon Bérard</name>
      <address>
        <city>Lyon</city>
        <zip>69373</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncologie Hôpital François Quesnay</name>
      <address>
        <city>Mantes-la-Jolie</city>
        <zip>78200</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karima SABOUNDJI</last_name>
      <email>karimasaboundji@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumologie Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <zip>130003</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncologie Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <zip>13273</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne MADROSZYK</last_name>
      <email>madroszyka@ipc.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Nord</name>
      <address>
        <city>Marseille</city>
        <zip>13915</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital de Meaux</name>
      <address>
        <city>Meaux</city>
        <zip>77100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncologie Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <zip>34298</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Camille TRAVERT</last_name>
      <email>camille.travert@icm.unicancer.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologie CH Morlaix</name>
      <address>
        <city>Morlaix</city>
        <zip>29600</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Karim AMRANE</last_name>
      <email>kamrane@ch-morlaix.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumologie CHR</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hugues H MOREL</last_name>
      <email>hugues.morel@chr-orleans.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oncologie Institut Curie</name>
      <address>
        <city>Paris</city>
        <zip>75005</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine DANIEL</last_name>
      <email>catherine.daniel@curie.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumologie Centre Hospitalier</name>
      <address>
        <city>Pau</city>
        <zip>64000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Aldo RENAULT</last_name>
      <email>also.renault@ch-pau.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital du Haut Leveque</name>
      <address>
        <city>Pessac</city>
        <zip>33604</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>CHU Pontchailloux</name>
      <address>
        <city>Rennes</city>
        <zip>35000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hôpital Charles Nicolle</name>
      <address>
        <city>Rouen</city>
        <zip>76031</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pneumologie Hôpital Yves Le Foll</name>
      <address>
        <city>Saint-Brieuc</city>
        <zip>22000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gwenaelle LE GARFF</last_name>
      <email>gwenaelle.legarff@ch-stbrieuc.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <zip>42271</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centre Paul Strauss</name>
      <address>
        <city>Strasbourg</city>
        <zip>67065</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pneumologie Hôpital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92150</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Hélène DOUBRE</last_name>
      <email>h.doubre@hopital-foch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumologie HIA</name>
      <address>
        <city>Talence</city>
        <zip>33400</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Michel PELONI</last_name>
      <email>jm.peloni@mspb.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumologie Hôpital Sainte Musse</name>
      <address>
        <city>Toulon</city>
        <zip>83056</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clarisse AUDIGIER VALETTE</last_name>
      <email>clarisse.audigier-valette@ch-toulon.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital d'Instruction des Armées Ste Anne</name>
      <address>
        <city>Toulon</city>
        <zip>83800</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BYLICKI</last_name>
      <phone>+33 483162937</phone>
      <email>bylicki.olivier@yahoo.fr</email>
    </contact>
    <investigator>
      <last_name>Olivier BYLICKI</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hôpital Larrey</name>
      <address>
        <city>Toulouse</city>
        <zip>31059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncologie CH Bretagne-Atlantique</name>
      <address>
        <city>Vannes</city>
        <zip>56000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gonzague DE CHABOT</last_name>
      <email>gonzague.dechabot@ch-bretagne-atlantique.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier de Villefranche sur Saone</name>
      <address>
        <city>Villefranche Sur Saone</city>
        <zip>69655</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Oncologie Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin BESSE</last_name>
      <email>benjamin.besse@gustaveroussy.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumologie CHI</name>
      <address>
        <city>Villeneuve-Saint-Georges</city>
        <zip>94195</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexa MAIROVITZ</last_name>
      <email>alexa.mairovitz@chiv.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Pneumologie CH Eure-Seine</name>
      <address>
        <city>Évreux</city>
        <zip>27000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nicolas DELBERGHE</last_name>
      <email>nicolas.delberghe@ch-eureseine.fr</email>
    </contact>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 6, 2021</study_first_submitted>
  <study_first_submitted_qc>November 4, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 17, 2021</study_first_posted>
  <last_update_submitted>November 4, 2021</last_update_submitted>
  <last_update_submitted_qc>November 4, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 17, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

